ProMed Pharma to highlight long-acting delivery capabilities at CPHI Milan and PODD Boston

ProMed Pharma plans to meet drug developers at two October industry events in Milan and Boston, where it will pitch its polymer-based controlled-release manufacturing capabilities for implants, injectables, and combination products. The company says the meetings will target pharmaceutical and biotech partners looking for support from feasibility through commercial cGMP supply.

Why it matters: - ProMed Pharma is positioning itself as a partner for drug developers working on long-acting therapies that require specialized polymer science and manufacturing. - The company is targeting programs that need controlled-release dosage forms, a market that often requires technical expertise across formulation, scale-up, and commercial production. - The events could connect ProMed Pharma with pharmaceutical and biotechnology companies looking for a single development and manufacturing partner.

What happened: - ProMed Pharma will attend CPHI Milan from October 6–8, 2026, at Fiera Milano in Milan, Italy. - ProMed Pharma will also attend PODD: Partnership Opportunities in Drug Delivery from October 29–30, 2026, at the Sheraton Boston Hotel in Boston, Massachusetts. - Business development and technical leaders from ProMed Pharma will meet with companies during both events.

The details: - ProMed Pharma plans to showcase capabilities in hot melt extrusion, injection molding of drug-loaded polymers, microencapsulation, and potent API handling. - The company works with polymeric excipients including silicones, thermoplastics, and biodegradables. - ProMed Pharma supports programs from early drug product feasibility studies through tech transfer, scale-up, clinical supply, and commercial cGMP manufacturing. - The company focuses on complex, polymer-based extended-release dosage forms, including drug-eluting implants, long-acting injectables, and drug-device combination products. - Attendees can contact ProMed Pharma at info@promedpharmallc.com or visit the company’s website to schedule a meeting.

Between the lines: - ProMed Pharma is emphasizing capabilities that matter most for long-acting drug delivery: materials science, device-compatible manufacturing, and scale-up readiness. - The timing suggests the company wants to use two major industry gatherings to broaden its pipeline of development and manufacturing partnerships. - James Arps, PhD, director of business development, said interest in polymer-based controlled release continues to grow and that long-acting delivery remains one of the most active areas in the industry.

What's next: - ProMed Pharma will use the October events to discuss new programs with potential partners and identify opportunities for future development work. - The company is inviting attendees to set up meetings ahead of both conferences. - ProMed Pharma says it will continue supporting partners from early feasibility through commercial supply.